Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors.
Johnson
Neil
N
Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, MA 02215, USA.
Shapiro
Geoffrey I
GI